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Partial remission in patients newly diagnosed with type 1 diabetes
is a period of good glucose control that can last from several weeks
to over a year. The clinical signiﬁcance of the remission period is
that patients might be more responsive to immunotherapy if
treated within this period. This article provides clinical data that
indicates the level of glucose control and insulin-secreting β-cell
function of each patient in the study at baseline (within 3 months
of diagnosis), and at 3, 6, 9, 12, 18 and 24 months post-baseline.
The relative frequency of immune cell subsets in the PBMC of each
patient and the association between the frequency of immune cell
subsets measured and length of remission is also shown. These
data support the ﬁndings reported in the accompanying publica-
tion, “A pilot study showing associations between frequency of
CD4þ memory cell subsets at diagnosis and duration of partial
remission in type 1 diabetes” (Moya et al., 2016) [1], where a full
interpretation, including biological relevance of the study can
be found.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.clim.2016.04.012
A. Narsale et al. / Data in Brief 8 (2016) 1348–1351 1349Speciﬁcations TableS
M
T
H
D
E
E
Dubject area Biology
ore speciﬁc sub-
ject areaImmunology of patients newly diagnosed with type 1 diabetesype of data Tables, Figures
ow data was
acquiredFlow Cytometryata format Raw, analyzed
xperimental
factorsFrozen peripheral blood mononuclear cells (PBMC) are thawed and stained with
panels of monoclonal antibodies speciﬁc for markers that deﬁne T cell subsets.xperimental
featuresThe relative frequency of T cell subsets is determined by Flow Cytometry using an
LSRFortessa for acquisition and FlowJo software for analysis.ata source
locationUnited Statesata accessibility Data is provided within this article.DValue of the data
 The data can be added to a larger patient data base to determine average length of partial
remission and β-cell function over time in children diagnosed with type 1 diabetes between 9 and
16 years of age.
 Identifying a predictor at diagnosis that can predict length of remission in children with type
1 diabetes might be used to stratify and select patients most likely to respond to immunotherapy.
 These data introduce a multimetric approach that might be useful in predicting disease progression
that might be applicable to a variety of disease states and stages including progression to type
1 diabetes, cancer progression, and responsiveness to immunotherapy.1. Data
The data provided in this article show the IDAA1c (Supplementary Table 1A) and C-peptide levels
(Supplementary Table 1B) for each patient in the study at baseline (within 3 months of diagnosis) and
at 3, 6, 9, 12, 18 and 24 months post-baseline. Supplementary Table 2 shows the relative frequency of
CD4þ CD45ROþ cells, activated Treg, and CD4þ CD25þ CD127hi cells in PBMC at baseline and at
3 months post-baseline, stratifying patients into those with either good (Supplementary Table 2A) or
poor glycemic control (Supplementary Table 2B). For patients with good glycemic control, the asso-
ciation between the frequency of each cell subset at baseline with length of time the HbA1c levels are
maintained below 7% (Supplementary Fig. 1), and at 3 months with length of remission using IDAA1c
(Supplementary Fig. 2) is shown.2. Experimental design and materials and methods
2.1. Patient population
Archived peripheral blood mononuclear cells (PBMC) from 9 female and 10 male newly diagnosed
type 1 diabetic patients were obtained from TrialNet Ancillary Studies. Patients were between 9 and
16 years of age and enrolled in the placebo groups of TrialNet clinical trials. Two PBMC samples from
each patient were analyzed, one taken at baseline (within 3 months of diagnosis) and one 3 months
later. The study was blinded. Clinical parameters were evaluated at baseline and again at 3, 6, 9, 12, 18,
and 24 months post-baseline.
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A standard formula, HbA1c (%)þ(4 insulin dose (U/kg per 24 h), is used to take into account both
insulin requirement and HbA1c levels in a single value, the Insulin Dose Adjusted A1c (IDAA1c) [2]. An
IDAA1c equal to or less than 9 indicates the partial remission period [3]. Partial remission measured
using IDAA1c is associated with a C-peptide AUC120 level of at least 108, equivalent to a mean C-
peptide level of 0.9 ng/ml/min or 0.3 pmol/ml [2]. In this study the end of partial remission is
between the last visit when IDAA1c is equal to or less than 9 and the ﬁrst visit when IDAA1c is greater
than 9. A more accurate estimate of time of end of partial remission was determined by interpolating
between these two observed values. Length of remission is the time between diagnosis and end of
remission. Stimulated C-peptide was measured in ng/ml and AUC calculated over 120 min using the
trapezoidal rule, with observed C-peptide values at 0, 15, 30, 60, 90, and 120 min.2.3. Type 1 diabetes PBMC analysis by Flow Cytometry
Vials of PBMC from patients with T1D were thawed and stained with each of the following panels
of mAbs. Healthy subject PBMC were thawed and used as positive controls for mAb staining in each
experiment. To identify memory (CD45RA , CD45ROþ) cells within the total CD4 compartment we
used either APC-conjugated anti-CD4 (BioLegend, clone OKT4) with PerCP-Cy5-5-conjugated anti-
CD3 (BioLegend, clone OKT3), PE-conjugated anti-CD45RO (BioLegend, clone UCHL1), and APC-H7-
conjugated anti-CD45RA (BD Biosciences, clone HI100). To identify CD4þ CD25þ CD127hi (CD25þ
CD127hi) we used the BD Biosciences Treg cocktail (FITC-conjugated anti-CD4 (clone SH3), Alexa Fluor
647-conjugated anti-CD127 (clone HIL-7R-M21), and PE-Cy7-conjugated anti-CD25 (clone 2A3)), with
PerCP-Cy5-5-conjugated anti-CD3. Activated Treg were identiﬁed using FITC-conjugated anti-CD4
(BioLegend, clone OKT4), APC-H7-conjugated anti-CD45RA and PerCP-Cy5.5-conjugated anti-Foxp3
(BD Biosciences, clone 236a/E7), using a standard published protocol used to identify activated Treg
[4]. Data were acquired on an LSRFortessa. Isotype controls were used in every experiment and for
every antigen-speciﬁc antibody. Additional CD4þ naïve and memory cell subsets were analyzed but
none showed a signiﬁcant correlation with length of partial remission [1].2.4. Statistics
Associations of clinical variables with either length of time the HbA1c was maintained below 7%,
or length of partial remission were assessed through Pearson correlations. All analyses were per-
formed with Graphpad Prism.Acknowledgments
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